Company: SUPN
Filing Date: 2025-02-24
Form Type: 8-K
Source: 0001356576-25-000011
Chunk: 3

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-24
Form: 8-K
Item: Item 9.01
Chunk 3
---
Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit 10.1 - Form of Non-Statutory Time-Based Stock Option Agreement, under the Supernus Pharmaceuticals, Inc. Amended and Restated 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.40 to the Form 10-K filed on February 27, 2024, File No. 001-35518).

Exhibit 10.2 - Form of Restricted Stock Unit Award Agreement, under the Supernus Pharmaceuticals, Inc. Amended and Restated 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.42 to the Form 10-K filed on February 27, 2024, File No. 001-35518).

Exhibit 10.3 - Form of Performance Share Unit Award Agreement, for awards issued after 2024 under the Supernus Pharmaceuticals, Inc. Amended and Restated 2021 Equity Incentive Plan.

Exhibit 104 - The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                SUPERNUS PHARMACEUTICALS, INC.                                                         
  DATED: February 24, 2025      By:                                 /s/ Timothy Dec                                    
                                                                    Timothy Dec                                        
                                                                    Senior Vice-President and Chief Financial Officer